Quality & complianceOfficial

Hikma recalls ciprofloxacin tablets nationwide in US over nitrosamine impurity above FDA interim limit

🇺🇸 FDA enforcement report · Wed 11 Nov 2026

An FDA Class II recall covers Hikma ciprofloxacin tablets after N-nitroso-ciprofloxacin results exceeded the agency's recommended interim control limit; the recall is ongoing.

The US Food and Drug Administration has listed a Class II recall of Ciprofloxacin Tablets from Hikma Pharmaceuticals USA Inc. in its enforcement report dated 11 November 2026. The recall carries the number D-0165-2027 and is shown as ongoing.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: FDA enforcement report ↗

Article written by VigiEye from the official source (FDA enforcement report). AI-assisted; check the source before acting.